Sullivan E A, Kreiswirth B N, Palumbo L, Kapur V, Musser J M, Ebrahimzadeh A, Frieden T R
New York City Department of Health, New York, USA.
Lancet. 1995 May 6;345(8958):1148-50. doi: 10.1016/s0140-6736(95)90980-x.
22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.
1991年1月至1993年11月期间，在纽约市确认了22例感染耐氟喹诺酮结核分枝杆菌的患者。16例患者的耐药性是由于治疗不足或不当所致。6例患者原发性感染耐氟喹诺酮病原体；5例患者是在医院获得该病原体。在21例患者的分离株中鉴定出7种不同的限制性片段长度多态性模式。氟喹诺酮类药物应仅限于患有耐多药疾病或对其他抗结核药物不耐受的患者使用。所有耐多药结核病患者均应接受直接观察治疗。
